Phuturdex › Diseases › Solitary fibrous tumor of the pleura
Drugs in development · updated 13 November 2026
Solitary fibrous tumor of the pleura: drugs in development
What it is
Solitary fibrous tumor (SFT), also known as fibrous tumor of the pleura, is a rare mesenchymal tumor originating in the pleura or at virtually any site in the soft tissue including the seminal vesicle. Approximately 78% to 88% of SFT's are benign and 12% to 22% are malignant. The World Health Organization (2020) classified SFT as a specific type of tumor in the category of malignant fibroblastic and myofibroblastic tumors.
Description not checked by Phuturdex: excerpt from the introduction of the article “Solitary fibrous tumor” on English Wikipedia, en.wikipedia.org · version of 25 April 2026 · licence CC BY-SA 4.0.
As of 13 November 2026 there are 2 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for solitary fibrous tumor of the pleura. One is experimental, that is not yet approved in the United States.
In Phuturdex every drug has its map of sites in Europe, every trial and its alerts, and you get an email when something changes. Full access free until 31 March 2027, no card needed.
Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OKN4395 | I | 1 | NCT06789172 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RepotrectinibAugtyro®, TPX-0005 | I–II | 1 | NCT04094610 |
| PembrolizumabKEYTRUDA, MK-3475 | I | 1 | NCT06789172 |
Sorted by most advanced phase and number of active trials.
Sites in Europe
34 sites of the active trials in 5 European countries, 25 recruiting.
- Spain11
- France10
- United Kingdom10
- Italy2
- Denmark1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Neoplasm 3,379 drugs
- Glandular and epithelial neoplasm 1,210 drugs
- Hemic and lymphatic diseases 1,330 drugs
- Lymphoproliferative disorders 806 drugs
- Lymphatic system disease 723 drugs
- Immunoproliferative disorder 796 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D054364 “Solitary Fibrous Tumors”.